KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

NCT04469725 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
95
Enrollment
INDUSTRY
Sponsor class

Stopped The termination of this study does not involve safety issues. The overall safety of KN046 is good, and no new safety signals have been found. The decision to terminate this study was made due to the adjustment of the sponsor's development strategy.

Conditions

Interventions

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd